<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323387</url>
  </required_header>
  <id_info>
    <org_study_id>1255</org_study_id>
    <nct_id>NCT01323387</nct_id>
  </id_info>
  <brief_title>Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer</brief_title>
  <acronym>ATB</acronym>
  <official_title>Lumbar Degenerative Disc Disease Treated With</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synthes USA HQ, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synthes USA HQ, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective nonrandomized study of treatment for 1 and 2 level degenerative
      disc disease between L2 and S1. Patients will be followed for a minimum of 2 years.

      The primary objective of this study to measure fusion success in patients with lumbar
      degenerative disc disease using the ATB and ALIF/FRA Spacer. The Secondary objective is
      evaluation of the patient's quality of life, pain and function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2004</start_date>
  <completion_date type="Actual">February 1, 2011</completion_date>
  <primary_completion_date type="Actual">May 1, 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Successful Radiographic Fusion</measure>
    <time_frame>24 Months</time_frame>
    <description>CT Scans and plain film x-rays will be evaluated. Demonstration of bridging trabecular bone through or external to the allograft spacer will be the measure of success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Using the SF-12 Scale Physical Health Component Score (PCS). Number of Subjects Who Achieved 15% Improvement in PCS Compared to Baseline.</measure>
    <time_frame>24 Months</time_frame>
    <description>Quality of Life using the SF-12 Scale Physical Health Component Score (PCS). The PCS is a measurement of health status with a range of 0-100. A higher score indicates less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>The Numeric Rating Scale (NRS) is a measurement of pain from a value of 0 (no pain) to a value of 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI): Number of Subjects Who Achieved a 15% Improvement in ODI Compared to Baseline</measure>
    <time_frame>24 Months</time_frame>
    <description>The outcome measure is the number of subjects who achieved a 15% improvement in ODI compared to baseline. The ODI is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to quantify disability for low back pain. ODI scores range from 0 to 100 with 0 equating to No Disability and 100 equating to the Maximum Disability Possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Using SF-12 Scale (MCS): Number of Subjects Who Achieved 15% Improvement in MCS Compared to Baseline</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>The outcome measure is the number of subjects who achieved a 15% improvement in MCS compared to baseline. The MCS (Mental Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 Physical Composite Score (PCS) Summary</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>The PCS (Physical Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 Mental Composite Score (MCS) Summary</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>The MCS (Mental Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI) Summary</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>The Oswestry Disability Index (ODI) is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to quantify disability for low back pain. The scores can range from 0 to 100 with 0 equating to No Disability and 100 equating to the Maximum Disability Possible</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Lumbar Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Interbody fusions with Anterior Plating</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interbody Fusion</intervention_name>
    <description>allograft spacer + anterior plate</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>ATB</other_name>
    <other_name>Anterior Tension Band</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. One or Two level (consecutive) degenerative disc disease between L2 and S1.
             Degenerative disc disease is defined as follows:

             Chronic pain (confirmed by patient exams and history) of discogenic origin, confirmed
             by radiographic evidence (e.g. MRI, discogram) two or more of the following:

               -  Modic type 2 endplate changes on T2 weighted MRI

               -  high intensity zone signal on T2 weighted MRI

               -  positive discogram with negative controls

               -  dark disc (diminished T2 weighted signal)

               -  decreased disc height

          2. Has experienced pain, functional deficit and/or neurological deficit for a minimum six
             month period of time prior to enrollment

          3. Has failed to respond to non-operative treatment modalities for a minimum three month
             period of time prior to enrollment

          4. Skeletally mature and at least 18 years of age

          5. Signs the approved Informed Consent Document

          6. Is available for long term follow-up and interval visits

        Exclusion Criteria:

          1. Has more than 2 levels to be instrumented

          2. Has had a previous fusion attempt at the involved level(s)

          3. Has had more than two previous open, lumbar spine surgical procedures at the involved
             level(s)

          4. Currently implanted with anterior instrumentation at the involved level(s)

          5. Patient would be classified as morbidly obese BMI &gt; 35

          6. Active localized or systemic infection

          7. Presence of a disease entity or condition which significantly affects the possibility
             of bony fusion (e.g., osteoporosis, metastatic cancer, long-term use of steroids,
             etc.)

          8. Has an immunosuppressive disorder

          9. Pregnant or interested in becoming pregnant during the study.

         10. Has a known sensitivity to device materials

         11. Mentally incompetent or prisoner

         12. Currently a participant in another study for the same indications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirkham Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mass. General Hospital</affiliation>
  </overall_official>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>April 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Interbody fusions with Anterior Plating</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Radiographic Data Unavailable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Revision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>178 subjects were enrolled in the study but 16 of these were never treated. A total of 162 subjects were both enrolled and treated.
Of the 162 enrolled and treated subjects, 12 were excluded for protocol deviations. Therefore, the overall number of baseline participants was 150 subjects per protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Interbody fusions with Anterior Plating</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Successful Radiographic Fusion</title>
        <description>CT Scans and plain film x-rays will be evaluated. Demonstration of bridging trabecular bone through or external to the allograft spacer will be the measure of success.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Interbody fusions with Anterior Plating</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Successful Radiographic Fusion</title>
          <description>CT Scans and plain film x-rays will be evaluated. Demonstration of bridging trabecular bone through or external to the allograft spacer will be the measure of success.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Using the SF-12 Scale Physical Health Component Score (PCS). Number of Subjects Who Achieved 15% Improvement in PCS Compared to Baseline.</title>
        <description>Quality of Life using the SF-12 Scale Physical Health Component Score (PCS). The PCS is a measurement of health status with a range of 0-100. A higher score indicates less disability.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Physical Health Composite Score (PCS)</title>
            <description>A self-reported quality of life assessment to measure a participant's interpretation of their physical well-being. A 15% improvement was considered a success.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Using the SF-12 Scale Physical Health Component Score (PCS). Number of Subjects Who Achieved 15% Improvement in PCS Compared to Baseline.</title>
          <description>Quality of Life using the SF-12 Scale Physical Health Component Score (PCS). The PCS is a measurement of health status with a range of 0-100. A higher score indicates less disability.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores on the Numeric Rating Scale (NRS)</title>
        <description>The Numeric Rating Scale (NRS) is a measurement of pain from a value of 0 (no pain) to a value of 10 (worst pain)</description>
        <time_frame>Baseline and 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Interbody fusions with Anterior Plating</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on the Numeric Rating Scale (NRS)</title>
          <description>The Numeric Rating Scale (NRS) is a measurement of pain from a value of 0 (no pain) to a value of 10 (worst pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NRS at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oswestry Disability Index (ODI): Number of Subjects Who Achieved a 15% Improvement in ODI Compared to Baseline</title>
        <description>The outcome measure is the number of subjects who achieved a 15% improvement in ODI compared to baseline. The ODI is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to quantify disability for low back pain. ODI scores range from 0 to 100 with 0 equating to No Disability and 100 equating to the Maximum Disability Possible</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Interbody fusions with Anterior Plating</description>
          </group>
        </group_list>
        <measure>
          <title>Oswestry Disability Index (ODI): Number of Subjects Who Achieved a 15% Improvement in ODI Compared to Baseline</title>
          <description>The outcome measure is the number of subjects who achieved a 15% improvement in ODI compared to baseline. The ODI is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to quantify disability for low back pain. ODI scores range from 0 to 100 with 0 equating to No Disability and 100 equating to the Maximum Disability Possible</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Using SF-12 Scale (MCS): Number of Subjects Who Achieved 15% Improvement in MCS Compared to Baseline</title>
        <description>The outcome measure is the number of subjects who achieved a 15% improvement in MCS compared to baseline. The MCS (Mental Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
        <time_frame>Baseline and 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Physical Health Composite Score (MCS)</title>
            <description>A self-reported quality of life assessment to measure a participant's interpretation of their physical well-being. A 15% improvement was considered a success.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Using SF-12 Scale (MCS): Number of Subjects Who Achieved 15% Improvement in MCS Compared to Baseline</title>
          <description>The outcome measure is the number of subjects who achieved a 15% improvement in MCS compared to baseline. The MCS (Mental Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12 Physical Composite Score (PCS) Summary</title>
        <description>The PCS (Physical Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
        <time_frame>Baseline and 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Interbody fusions with Anterior Plating</description>
          </group>
        </group_list>
        <measure>
          <title>SF-12 Physical Composite Score (PCS) Summary</title>
          <description>The PCS (Physical Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12 Mental Composite Score (MCS) Summary</title>
        <description>The MCS (Mental Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
        <time_frame>Baseline and 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Interbody fusions with Anterior Plating</description>
          </group>
        </group_list>
        <measure>
          <title>SF-12 Mental Composite Score (MCS) Summary</title>
          <description>The MCS (Mental Component Score) is a measurement of health status with a range of 0 to 100. A higher score indicates less disability.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oswestry Disability Index (ODI) Summary</title>
        <description>The Oswestry Disability Index (ODI) is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to quantify disability for low back pain. The scores can range from 0 to 100 with 0 equating to No Disability and 100 equating to the Maximum Disability Possible</description>
        <time_frame>Baseline and 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Interbody fusions with Anterior Plating</description>
          </group>
        </group_list>
        <measure>
          <title>Oswestry Disability Index (ODI) Summary</title>
          <description>The Oswestry Disability Index (ODI) is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to quantify disability for low back pain. The scores can range from 0 to 100 with 0 equating to No Disability and 100 equating to the Maximum Disability Possible</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ODI at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODI at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Interbody fusions with Anterior Plating</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Broken Components</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Device Slippage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Disc Fragment Dislodged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>New Onset of Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Pseudoarthrosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Soft Tissue Damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vascular Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Hematoma/Seroma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Intestinal Blockage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Broken Components</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Disc Fragment Dislodged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Motor Vehicle Accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudoarthrosis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Adjacent Segment Degeneration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Fracture of Vertebrae</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Muscle Spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Soft Tissue Damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cysts Found in and around Spacer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>New Onset of Pain</sub_title>
                <counts group_id="E1" events="54" subjects_affected="38" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Numbness/Tingling Sensation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Neural Structure Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Slippage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Menstrual Cycle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Retrograde Ejaculation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Injury</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombophlegitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Associate</name_or_title>
      <organization>Synthes Spine</organization>
      <phone>610-719-5942</phone>
      <email>knappk@synthes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

